Casdozokitug is under clinical development by Surface Oncology and currently in Phase II for Squamous Non-Small Cell Lung Carcinoma. According to GlobalData, Phase II drugs for Squamous Non-Small Cell Lung Carcinoma have a 38% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Casdozokitug’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Casdozokitug (SRF-388) is under development for the treatment of solid tumors including renal cell cancer, non-small-cell lung cancer, squamous cell non-small-cell lung carcinoma, hepatocellular cancer and metastatic hepatocellular cancer. It is a monoclonal antibody acts by targeting cytokine IL-27. It is administered through intravenous route.
It was also under development for the treatment of lung cancer.
Surface Oncology overview
Surface Oncology is an immuno-oncology company. It develops novel antibody therapies for the treatment of cancer. The company’s product portfolio includes SRF388, to treat various diseases like renal cell carcinoma, hepatocellular carcinoma, and non-small-cell lung cancer; SRF617, to treat various tumors like gastric cancer, prostate cancer, PD-(L)1 relapsed cancer, and pancreatic cancer. Surface Oncology also provides SRF114, NZV930 and GSK4381562 antibodies. It also carries out research and development activities and pre-clinical studies. The company has entered two strategic collaborations to advance our next-generation cancer therapies partners which include Novartis and GSK. Surface Oncology is headquartered in Cambridge, Massachusetts, the US.
For a complete picture of Casdozokitug’s drug-specific PTSR and LoA scores, buy the report here.